Janux Therapeutics, Inc. (JANX) - 10-K Summary
Business Context and Reporting Period
Company: Janux Therapeutics, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Janux is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and autoimmune diseases. The company utilizes three proprietary platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $10.0 | $10.6 |
| Research & Development Expenses | $125.9 | $68.4 |
| General & Administrative Expenses | $41.8 | $41.0 |
| Net Loss | $(113.6) | $(69.0) |
| Cash, Cash Equivalents & Short-Term Investments | $967.4 | $1,025.2 |
| Accumulated Deficit | $(351.4) | $(237.8) |
Liquidity: As of December 31, 2025, the company held $967.4 million in cash, cash equivalents, and short-term investments. Management estimates these resources are sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue: Collaboration revenue decreased by $0.6 million (5.5%) to $10.0 million. This decrease was primarily due to the completion of research services under the Merck collaboration in August 2024, partially offset by the recognition of a $10.0 million milestone payment in August 2025.
- Operating Expenses: Total operating expenses increased by $58.2 million (53.2%) to $167.7 million.
- R&D Expenses: Increased by $57.5 million (84.1%) to $125.9 million. The increase was driven by higher costs for preclinical stage programs ($31.0 million increase), indirect compensation costs ($16.2 million increase), and direct costs for lead candidates JANX007 ($9.2 million increase) and JANX008 ($1.1 million increase).
- G&A Expenses: Increased slightly by $0.7 million (1.8%) to $41.8 million, primarily due to higher compensation and other costs, offset by a decrease in stock-based compensation.
- Net Loss: Increased by $44.6 million (64.7%) to $113.6 million, reflecting the significant rise in R&D spending.
- Capital Raise: In December 2024, the company closed an underwritten offering raising net proceeds of $377.9 million. In March 2024, it raised net proceeds of $320.1 million.
Guidance, Outlook, and Management Commentary
Clinical Progress:
- JANX007 (PSMA-TRACTr): Phase 1a expansion cohorts demonstrated durability across once-weekly and every-two-week dosing. Preliminary Phase 1b data in taxane-naïve patients showed rapid PSA reductions with manageable safety (primarily Grade 1 CRS). The company initiated Phase 1b expansion cohorts in taxane-naïve mCRPC, combination with darolutamide, and post-PARP inhibitor therapy.
- JANX008 (EGFR-TRACTr): Initiated Phase 1a expansion cohorts in selected solid tumor indications based on efficacy and safety data from the dose-escalation portion.
- JANX011 (CD19-ARM): Initiated a Phase 1 clinical study in healthy volunteers for autoimmune diseases.
Strategic Collaborations:
- Merck: Research services completed in August 2024. A $10.0 million milestone was achieved in August 2025. Merck has the right to select up to two targets; both have been selected.
- Bristol Myers Squibb (BMS): In January 2026 (subsequent event), Janux entered an exclusive license and collaboration agreement. Janux received a $15.0 million upfront payment and is eligible for up to $785.0 million in milestone payments. Janux will conduct preclinical development until IND submission.
Risks and Contingencies:
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will need to raise substantial additional capital to complete development and commercialization.
- Regulatory Approval: All product candidates are in early clinical or preclinical stages. Success in early trials does not guarantee future results or regulatory approval.
- Manufacturing: Reliance on third-party manufacturers, including WuXi Biologics in China, exposes the company to supply chain and geopolitical risks.
- Intellectual Property: The company relies on patents and trade secrets; failure to obtain or maintain protection could harm the business.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $967.4 million cash balance against the accelerating burn rate (R&D expenses nearly doubled in 2025).
- Clinical Durability: Monitor upcoming data readouts for JANX007 Phase 1b expansion cohorts to confirm durability of response and safety profile in taxane-naïve patients.
- BMS Collaboration Terms: Review the specific milestones and timelines for the January 2026 BMS agreement to assess near-term revenue potential beyond the $15 million upfront.
- Manufacturing Dependencies: Assess the impact of potential trade restrictions or supply chain disruptions related to WuXi Biologics on clinical trial timelines.
- Stock-Based Compensation: Note the significant stock-based compensation expense ($40.2 million in 2025) and its impact on future dilution.